Investigation for intravesical recurrences between with and without BCG therapies according to history of therapeutic agents for dysuria in Non-muscle invasive bladder cancer

Investigation for intravesical recurrences between with and without BCG therapies according to history of therapeutic agents for dysuria in Non-muscle invasive bladder cancer - Investigation for intravesical recurrences between with and without BCG therapies according to history of therapeutic agents for dysuria in Non-muscle invasive bladder cancer

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000039043

Enrollment

200

Registered

2020-09-30

Start date

2020-01-02

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-muscle invasive bladder cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Age: 20 years or older, regardless of gender. 2) Urothelial carcinoma who became T1 or less by TUR-BT 3) ECOG PS 0 or 1 4) Expected to survive for more than 2 years 5) Patients who have given written informed consent prior to enrollment in this study 6) Patients who have not received other treatments for bladder cancer (immunotherapy, chemotherapy, molecular targeted therapy, investigational drugs) 7) Cases without serious organ complications in heart, lung, liver, kidney, etc.

Exclusion criteria

Exclusion criteria: 1) HIV infection or active chronic hepatitis 2) Active infection (grade 3 or higher according to CTCAE Version 4.0) 3) The cases judged by doctors to be inappropriate.

Design outcomes

Primary

Measure	Time frame
Recurrence	—

Countries

Japan

Contacts

Public ContactYoichiro Kato

Iwate Medical University Urology

ikyoku@urology-imu.jp019-613-7111

Outcome results